37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterization of Structure and Function of ZS-9, a K + Selective Ion Trap

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hyperkalemia, a condition in which serum potassium ions (K +) exceed 5.0 mmol/L, is a common electrolyte disorder associated with substantial morbidity. Current methods of managing hyperkalemia, including organic polymer resins such as sodium polystyrene sulfonate (SPS), are poorly tolerated and/or not effective. Sodium zirconium cyclosilicate (ZS-9) is under clinical development as an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound that selectively removes excess K + in vivo. The development, structure and ion exchange properties of ZS-9 and its hypothesized mechanism of action are described. Based on calculation of the interatomic distances between the atoms forming the ZS-9 micropores, the size of the pore opening was determined to be ∼3 Å (∼diameter of unhydrated K +). Unlike nonspecific organic polymer resins like SPS, the ZS-9 K + exchange capacity (KEC) was unaffected by the presence of calcium (Ca 2+) or magnesium ions (Mg 2+) and showed>25-fold selectivity for K + over either Ca 2+ or Mg 2+. Conversely, the selectivity of SPS for K + was only 0.2–0.3 times its selectivity for Ca 2+ or Mg 2+in mixed ionic media. It is hypothesized that the high K + specificity of ZS-9 is attributable to the chemical composition and diameter of the micropores, which possibly act in an analogous manner to the selectivity filter utilized by physiologic K + channels. This hypothesized mechanism of action is supported by the multi-ion exchange studies. The effect of pH on the KEC of ZS-9 was tested in different media buffered to mimic different portions of the human gastrointestinal tract. Rapid K + uptake was observed within 5 minutes - mainly in the simulated small intestinal and large intestinal fluids, an effect that was sustained for up to 1 hour. If approved, ZS-9 will represent a novel, first-in-class therapy for hyperkalemia with improved capacity, selectivity, and speed for entrapping K + when compared to currently available options.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

          Sodium polystyrene sulfonate (SPS), an ion-exchange resin designed to bind potassium in the colon, was approved in 1958 as a treatment for hyperkalemia by the US Food and Drug Administration, 4 years before drug manufacturers were required to prove the effectiveness and safety of their drugs. In September 2009, citing reports of colonic necrosis, the Food and Drug Administration issued a warning advising against concomitant administration of sorbitol, an osmotic cathartic used to prevent SPS-induced fecal impaction and to speed delivery of resin to the colon, with the powdered resin; however, a premixed suspension of SPS in sorbitol, the only preparation stocked by many hospital pharmacies, is prescribed routinely for treatment of hyperkalemia. We can find no convincing evidence that SPS increases fecal potassium losses in experimental animals or humans and no evidence that adding sorbitol to the resin increases its effectiveness as a treatment for hyperkalemia. There is growing concern, however, that suspensions of SPS in sorbitol can be harmful. It would be wise to exhaust other alternatives for managing hyperkalemia before turning to these largely unproven and potentially harmful therapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pathogenesis, diagnosis and management of hyperkalemia

            Hyperkalemia is a potentially life-threatening condition in which serum potassium exceeds 5.5 mmol/l. It can be caused by reduced renal excretion, excessive intake or leakage of potassium from the intracellular space. In addition to acute and chronic renal failure, hypoaldosteronism, and massive tissue breakdown as in rhabdomyolysis, are typical conditions leading to hyperkalemia. Symptoms are non-specific and predominantly related to muscular or cardiac dysfunction. Treatment has to be initiated immediately using different therapeutic strategies to increase potassium shift into the intracellular space or to increase elimination, together with reduction of intake. Knowledge of the physiological mechanisms of potassium handling is essential in understanding the causes of hyperkalemia as well as its treatment. This article reviews the pathomechanisms leading to hyperkalemic states, its symptoms, and different treatment options.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

              Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS). We evaluated the benefits and harms of adding selective and nonselective AA in CKD patients already on RAS. MEDLINE, EMBASE, and Renal Health Library were searched for relevant randomized clinical trials in adult CKD patients. Results were summarized using the random-effects model. Eleven trials (991 patients) were included. In comparison to angiotensin- converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB) plus placebo, nonselective AA along with ACEi and/or ARB significantly reduced 24 h proteinuria (seven trials, 372 patients, weighted mean difference [WMD] -0.80 g, 95% CI -1.27, -0.33) and BP. This did not translate into an improvement in GFR (WMD -0.70 ml/min/1.73m(2), 95% CI -4.73, 3.34). There was a significant increase in the risk of hyperkalemia with the addition of nonselective AA to ACEi and/or ARB (relative risk 3.06, 95% CI 1.26, 7.41). In two trials, addition of selective AA to ACEi resulted in an additional reduction in 24 h proteinuria, without any impact on BP and renal function. Data on cardiovascular outcomes, long-term renal outcomes and mortality were not available in any of the trials. Aldosterone antagonists reduce proteinuria in CKD patients already on ACEis and ARBs but increase the risk of hyperkalemia. Long-term effects of these agents on renal outcomes, mortality, and safety need to be established.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                22 December 2014
                : 9
                : 12
                : e114686
                Affiliations
                [1 ]ZS Pharma Inc., Coppell, Texas, United States of America
                [2 ]Xelay Acumen, Inc., Belmont, California, United States of America
                RMIT University, Australia
                Author notes

                Competing Interests: The authors have read the journal's policy and have the following competing interests: ZS Pharma, Inc. is the commercial funder of this study. F. Stavros, M. Nuttall, and H. Rasmussen are employees of ZS Pharma Inc. and hold stock or stock options in ZS Pharma, Inc. A. Leon is an employee of ZS Pharma Inc., holds stock or stock options in ZS Pharma, Inc., and is named on two patents held by ZS Pharma Inc. A. Yang is employed by Xelay Acumen, Inc., is a paid consultant to ZS Pharma, Inc., and holds stock options in ZS Pharma, Inc. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: AL FS MN AY HR. Performed the experiments: AL MN. Analyzed the data: AL MN FS AY HR. Contributed reagents/materials/analysis tools: AL MN. Wrote the paper: FS AL MN HR AY.

                Article
                PONE-D-14-35641
                10.1371/journal.pone.0114686
                4273971
                25531770
                f1580501-d0b3-47f5-85f8-2cae63cbd63a
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 8 August 2014
                : 12 November 2014
                Page count
                Pages: 12
                Funding
                These studies were funded by ZS Pharma, Inc. http://www.zspharma.com/. The funder had a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.
                Categories
                Research Article
                Biology and Life Sciences
                Biophysics
                Ion Transport
                Physiology
                Electrophysiology
                Medicine and Health Sciences
                Cardiology
                Cardiovascular Pharmacology
                Nephrology
                Chronic Kidney Disease
                Pharmaceutics
                Drug Therapy
                Drug Administration
                Pharmaceutical Engineering
                Pharmacology
                Drug Research and Development
                Drug Design
                Drug Discovery
                Drug Information
                Physical Sciences
                Chemistry
                Electrochemistry
                Electrolytes
                Physical Chemistry
                Ions
                Cations
                Custom metadata
                The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

                Uncategorized
                Uncategorized

                Comments

                Comment on this article